VTVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
vTv Therapeutics Inc (VTVT) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. While the company has promising developments in its pipeline and strong analyst support, the lack of immediate positive trading signals, weak financial performance, and a bearish short-term stock trend suggest holding off for now.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock has a high probability of declining in the short term (-3.86% in the next week and -8.55% in the next month). Key support is at $30.044, and resistance is at $38.689.
Analysts are bullish with multiple Buy ratings and price targets ranging from $47 to $67, citing the potential of cadisegliatin for Type 1 diabetes.
The FDA's prioritization of T1D therapies and the drug's Breakthrough Therapy Designation are positive indicators.
The Phase 3 program's potential to replicate compelling Phase 2 results could drive future growth.
Financial performance is weak, with no revenue growth, negative net income, and declining gross margin.
Stock trend analysis suggests bearish short-term performance.
Lack of recent news or significant insider/hedge fund trading activity.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$8.7M (though improved by 81.85% YoY), and an EPS of -1.08 (up 22.73% YoY). Gross margin dropped to 0%, reflecting poor operational efficiency.
Analysts are highly optimistic, with Buy ratings from BTIG, Roth Capital, and TD Cowen. Price targets range from $47 to $67, reflecting confidence in the company's lead drug, cadisegliatin, and its potential market impact.
